Status:
COMPLETED
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Lead Sponsor:
Taipei City Hospital
Conditions:
COVID-19 Pandemic
Eligibility:
All Genders
Brief Summary
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during...
Detailed Description
The large-scale coronavirus epidemic is a major global public health challenge in the 21st century. Since the 2003 Severe acute respiratory syndrome (SARS) epidemic spread globally and caused hundreds...
Eligibility Criteria
Inclusion
- \- From January 1, 2020 to July 31, 2021, Chinese medicine is used for patients with new coronary pneumonia epidemic prevention.
Exclusion
- Patients who do not use traditional Chinese medicine for the prevention of new coronary pneumonia.
- Patients who have signed and refused to provide medical records.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 18 2021
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05236309
Start Date
January 1 2020
End Date
November 18 2021
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei City Hospital
Taipei, Taiwan, 886